223 related articles for article (PubMed ID: 14281008)
1. THE INFLUENCE OF ISOLATED PROPERDIN ON HELA-AND DETROIT 6-CELLS IN VITRO.
RERABKOVA E; RYBAK M; PETAKOVA M; PESKOVA D
Blut; 1964; 10():371-82. PubMed ID: 14281008
[No Abstract] [Full Text] [Related]
2. [ULTRACENTRIFUGE STUDIES ON PROPERDIN SERA OF ZYMOSAN-VACCINATED CATTLE, RABBITS, GUINEA PIGS, RATS AND MICE AND ON BOVINE PROPERDIN SERUM FRACTIONS].
ZIMMERMANN G; KRUEGER K
Acta Biol Med Ger; 1963; 11():902-17. PubMed ID: 14121884
[No Abstract] [Full Text] [Related]
3. THE EFFECT OF IMMUNE SERUM AND ACTIVATOR ON THE INFECTIVITY OF TOXOPLASMA GONDII FOR CELL CULTURE.
LYCKE E; LUND E; FALSEN E
Acta Pathol Microbiol Scand; 1965; 63():206-20. PubMed ID: 14302343
[No Abstract] [Full Text] [Related]
4. [APROPOS OF THE PYROGENICITY OF ZYMOSANS].
ZIMMERMANN G
Acta Biol Med Ger; 1964; 13():325-30. PubMed ID: 14251827
[No Abstract] [Full Text] [Related]
5. [OBSERVATION ON TUMORAL IMMUNITY IN CONNECTION WITH THE PROPERDIN SYSTEM].
NAGY IS; ATS M; KOSZORU M; LUST I
Sangre (Barc); 1964; 17():272-4. PubMed ID: 14218362
[No Abstract] [Full Text] [Related]
6. THE CLINICO-PATHOLOGICAL SIGNIFICANCE OF THE VARIABILITY OF THE SERUM-PROPERDIN-LEVEL IN TUMORS.
NAGY IS; KOSZORU M; MAJOROSSY K; VAJDA J
Acta Unio Int Contra Cancrum; 1964; 20():1241-3. PubMed ID: 14274746
[No Abstract] [Full Text] [Related]
7. [PREVENTION OF THE CONSEQUENCES OF TUMOR CELL DISSEMINATION IN BROWN-PEARCE TESTICULAR TUMOR IN RABBITS BY ADMINISTRATION OF MANNOZYM].
NAGY I; KOSZORU M; MAJOROSSY K; VAJDA J
Magy Onkol; 1964 Mar; 8():46-52. PubMed ID: 14141983
[No Abstract] [Full Text] [Related]
8. [THE ROLE OF THE PROPERDIN SYSTEM IN NON-SPECIFIC IMMUNITY].
HOSHINO A
Nihon Naika Gakkai Zasshi; 1963 Dec; 52():1023-40. PubMed ID: 14158037
[No Abstract] [Full Text] [Related]
9. [ON THE ACTION OF ANTI-KB SERUM ON KB CELLS].
PITZURRA M; COSTABILE F; SANTACROCE G; ROBERTI D
Nuovi Ann Ig Microbiol; 1964; 15():69-71. PubMed ID: 14185128
[No Abstract] [Full Text] [Related]
10. [EFFECT OF ZYMOSAN AND ITS FRACTIONS ON THE PROPERDIN LEVEL IN THE BLOOD AND ON THE MORPHOLOGY OF ORGANS AND TISSUES].
RUTBERG RA; LOSEVA GI; NEMONOVA NM; MALANINA VN
Biull Eksp Biol Med; 1964 Apr; 13():127-32. PubMed ID: 14248407
[No Abstract] [Full Text] [Related]
11. [PROPERDIN AND ANAPHYLATOXIN].
WILLEMS G
Rev Immunol Ther Antimicrob; 1963; 27():285-90. PubMed ID: 14111198
[No Abstract] [Full Text] [Related]
12. H-ANTIGEN IN HELA CELLS AND H-ANTIBODIES IN ANTI-HELA SERA.
BRAND G; YUNIS E; YUNIS J
Nature; 1963 Oct; 200():362. PubMed ID: 14087887
[No Abstract] [Full Text] [Related]
13. [PHAGOCYTOSIS AND GROWTH OF TUBERCLE BACTERIA IN HELA CELL CULTURES].
SCHELLER S; SZURMAN J; SZAFLARSKI J
Zentralbl Bakteriol Orig; 1964 Feb; 192():86-94. PubMed ID: 14176853
[No Abstract] [Full Text] [Related]
14. A NEW METHOD FOR THE STUDY OF CYTOTOXIC SYSTEMS (SPECIFIC EVEN NON-SPECIFIC) OF BLOOD SERUMS.
RYBAK M; PETAKOVA M; SIMONIANOVA E
Z Immunitats Allergieforsch; 1963 Oct; 125():351-7. PubMed ID: 14117569
[No Abstract] [Full Text] [Related]
15. SOME RES EFFECTS INFLUENCING RADIATION SURVIVAL TIME.
SZANTO A
Acta Unio Int Contra Cancrum; 1964; 20():1233-5. PubMed ID: 14274743
[No Abstract] [Full Text] [Related]
16. [THE BEHAVIOR OF CIRCULATING ANTIBODIES AND PROPERDIN FOLLOWING SENSITIZATION WITH HOMOLOGOUS TISSUE ANTIGENS].
SCHEIFFARTH F; WARNATZ H; FRENGER W; HALFAR I; TYMPNER KD
Z Gesamte Exp Med; 1964 Feb; 138():81-91. PubMed ID: 14161934
[No Abstract] [Full Text] [Related]
17. The properdin system and immunity. XV. Some biologic effects of the administration of zvmosan and other polvsaccharides to rabbits, and the presence of antibodies to zymosan in human and rabbit serum.
HINZ CF; WEDGWOOD RJ; PILLEMER L
J Lab Clin Med; 1961 Feb; 57():185-98. PubMed ID: 13714488
[No Abstract] [Full Text] [Related]
18. Anaphylatoxin formation by contact activation of plasma. II. Implication of properdin and an unknown plasma factor in activation by zymosan.
Brade V; Vogt W
Eur J Immunol; 1971 Aug; 1(4):295-300. PubMed ID: 4945686
[No Abstract] [Full Text] [Related]
19. AN EXPERIENCE IN APPLYING SERA TO COUNTER MALIGNANT NEOFORMATIONS UNDER EXPERIMENTAL CONDITIONS.
MAISKY IN; AIRAPETIAN GP; KOZLOVA NA; NILOVSKY MN; SUVOROVA GV; SUKHORUKIKH SV; KHUNDANOVA LL
Acta Unio Int Contra Cancrum; 1964; 20():107-9. PubMed ID: 14151860
[No Abstract] [Full Text] [Related]
20. HOST DEFENCE AND CHEMOTHERAPY IN EXPERIMENTAL CANCER.
SOKOLOFF B; MCCONNELL B
Acta Unio Int Contra Cancrum; 1964; 20():209-10. PubMed ID: 14151887
[No Abstract] [Full Text] [Related]
[Next] [New Search]
